Primary-source record

MaterialApplication submitted

Larimar completes rolling BLA for nomlabofusp in Friedreich’s ataxia

Larimar completed its rolling BLA submission seeking accelerated approval of nomlabofusp based on skin frataxin as a potential novel surrogate endpoint, supported by open-label data showing sustained frataxin increases and directional clinical improvements. FDA previously aligned on the data package and surrogate endpoint approach. This advances the regulatory path with BLA acceptance expected in early 2027 and potential U.S. approval in mid-2027.

Key facts

Filed
Nov 9, 2026, 09:08 PM
Event
Application submitted
Direction
Positive
Source
SEC 8-K
Confidence
Sourced

Source excerpt

EX-99.1 2 lrmr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia • Completed BLA submission marks a major milestone in advancing nomlabofusp as the first potential disease-modifying therapy to address the underlying cause of FA • Submission follows FDA alignment on key elements of the BLA package for submission, including willingness to consider skin frataxin as a potential novel surrogate endpoint • Previously reported open label data showed sustained increases in skin frataxin with directional clinical improvements observed in multiple outcomes relative to a natural history reference population • Patients currently enrolling in FORWARD-FA, the global confirmatory Phase 3 study for nomlabofusp Bala Cynwyd, PA, November 9, 2026 – Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced completion of its rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of nomlabofusp for the treatment of patients with Friedreich’s ataxia (FA). Nomlabofusp is an investigational protein replacement therapy designed to address the underlying cause of FA, frataxin deficiency, by delivering human frataxin to mitochondria. Completion of the submission follows previously disclosed FDA feedback

SEC 8-K

More on this asset

Oct 27, 2026
03:21 PM
LRMRLarimar

nomlabofusp · NCT06447025 registry update

Trial registry changeClinicalTrials.gov
Oct 9, 2026
03:20 PM
LRMRLarimar

nomlabofusp · NCT06447025 registry update

Trial registry changeClinicalTrials.gov1 update
Mar 19, 2026
11:04 AM
LRMRLarimar

Larimar receives Breakthrough Therapy Designation for nomlabofusp in FA

FDA designationSEC 8-K
Feb 24, 2026
12:02 PM
LRMRLarimar

Larimar: FDA grants Breakthrough Therapy Designation to nomlabofusp in FA

FDA designationSEC 8-K
Jan 12, 2026
09:18 PM
LRMRLarimar

Larimar: nomlabofusp regulatory update expected Q1 2026; BLA Q2 2026

OtherSEC 8-K
Larimar completes rolling BLA for nomlabofusp in Friedreich’s ataxia | SimianX AI